Technical Analysis for GRTS - Gritstone Oncology, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.03 | -31.78% | -0.02 |
GRTS closed down 31.78 percent on Monday, October 21, 2024, on 2.65 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -31.78% | |
Calm After Storm | Range Contraction | -31.78% | |
NR7 | Range Contraction | -31.78% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Immunotherapies Virotherapy Biopsy Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Immunotherapies Virotherapy Biopsy Tumor Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.17 |
52 Week Low | 0.031 |
Average Volume | 21,017,655 |
200-Day Moving Average | 1.17 |
50-Day Moving Average | 0.40 |
20-Day Moving Average | 0.24 |
10-Day Moving Average | 0.08 |
Average True Range | 0.04 |
RSI (14) | 18.70 |
ADX | 42.17 |
+DI | 14.78 |
-DI | 48.63 |
Chandelier Exit (Long, 3 ATRs) | 0.53 |
Chandelier Exit (Short, 3 ATRs) | 0.16 |
Upper Bollinger Bands | 0.67 |
Lower Bollinger Band | -0.19 |
Percent B (%b) | 0.26 |
BandWidth | 357.60 |
MACD Line | -0.12 |
MACD Signal Line | -0.11 |
MACD Histogram | -0.0126 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.05 | ||||
Resistance 3 (R3) | 0.05 | 0.04 | 0.04 | ||
Resistance 2 (R2) | 0.04 | 0.04 | 0.04 | 0.04 | |
Resistance 1 (R1) | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Pivot Point | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Support 1 (S1) | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
Support 2 (S2) | 0.03 | 0.03 | 0.02 | 0.02 | |
Support 3 (S3) | 0.02 | 0.03 | 0.02 | ||
Support 4 (S4) | 0.02 |